Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Titel:
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Auteur:
Park, Keunchil Tan, Eng-Huat O'Byrne, Ken Zhang, Li Boyer, Michael Mok, Tony Hirsh, Vera Yang, James Chih-Hsin Lee, Ki Hyeong Lu, Shun Shi, Yuankai Kim, Sang-We Laskin, Janessa Kim, Dong-Wan Arvis, Catherine Dubos Kölbeck, Karl Laurie, Scott A Tsai, Chun-Ming Shahidi, Mehdi Kim, Miyoung Massey, Dan Zazulina, Victoria Paz-Ares, Luis